Trevi Therapeutics (TRVI) Change in Accured Expenses (2018 - 2026)

Trevi Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 28.38% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$989000.0 (down 149.4% YoY), while the FY2025 annual figure was -$1.4 million, down 155.21% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.1 million, down from -$555000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $2.2 million in Q3 2024, with the low at -$1.5 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $14000.0 (2022), against an average of -$30235.3.
• Peak annual rise in Change in Accured Expenses reached 375.27% in 2024, while the deepest fall reached 3070.83% in 2024.
• Trevi Therapeutics' Change in Accured Expenses stood at -$1.3 million in 2022, then surged by 101.85% to $24000.0 in 2023, then tumbled by 3070.83% to -$713000.0 in 2024, then advanced by 22.16% to -$555000.0 in 2025, then tumbled by 93.69% to -$1.1 million in 2026.
• Business Quant data shows TRVI's Change in Accured Expenses at -$1.1 million in Q1 2026, -$555000.0 in Q4 2025, and $143000.0 in Q3 2025.